Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Alvaia, Natália
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy	Recruiting	3	102	Europe, Canada, US, RoW	Ampreloxetine, TD-9855, Placebo	Theravance Biopharma	Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy	12/24	01/27
Qi, Angela-Ji Yao
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy	Recruiting	3	102	Europe, Canada, US, RoW	Ampreloxetine, TD-9855, Placebo	Theravance Biopharma	Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy	12/24	01/27